Major Depressive Disorder

Neurology·MeSH: Depressive Disorder, Major

Prevalence

5000.0 / 100K

Incidence

300.0 / 100K/yr

56 drugs in development·40 companies·38 clinical trials

Drug Pipeline by Phase

Approved(17)

Drug	Company
Auvelity	Axsome Therapeutics, Inc. (AXSM)
bupropion	Prestige Consumer Healthcare Inc. (PBH)
bupropion	ACADIA PHARMACEUTICALS INC (ACAD)
bupropion	Miromatrix Medical Inc. (MIRO)
bupropion	Design Therapeutics, Inc. (DSGN)
bupropion	AlphaTON Capital Corp (ATON)
bupropion	SUNSET ISLAND GROUP (SUN)
bupropion	Impax Laboratories, LLC (IPXL)
Cymbalta®	ELI LILLY & Co (LLY)
duloxetine	Inventiva S.A. (IVA)
EXXUA	AYTU BIOPHARMA, INC (AYTU)
neurostar advanced therapy system	Neuronetics Inc. (STIM)
paroxetine	OXFORD IMMUNOTEC GLOBAL PLC (OXFD)
paroxetine	Mylan II B.V. (MYL)
sertraline	Amneal Pharmaceuticals, Inc. (AMRX)
venlafaxine	Teva Pharmaceutical Industries Limited (TEVA)
zurzuvae	SUPERNUS PHARMACEUTICALS, INC. (SUPN)

Phase 3(15)

Drug	Company
azetukalner	Xenon Pharmaceuticals Inc. (XENE)
bysanti	Vanda Pharmaceuticals Inc. (VNDA)
centanafadine	NYMOX PHARMACEUTICAL CORP (NYMXF)
COMP360 psilocybin treatment	COMPASS Pathways plc (CMPS)
cyb003	CYBIN INC. (HELP)
CYB003	Crinetics Pharmaceuticals, Inc. (CRNX)
dt120	Definium Therapeutics Inc. (DFTX)
Epidiolex 100 mg/mL Oral Solution	COLLEGIUM PHARMACEUTICAL, INC (COLL)
MM-120	Definium Therapeutics Inc. (DFTX)
navacaprant	Neumora Therapeutics, Inc. (NMRA)
nbi-1065845	NEUROCRINE BIOSCIENCES INC (NBIX)
rel-1017	RELMADA THERAPEUTICS, INC. (RLMD)
solriamfetol	Axsome Therapeutics, Inc. (AXSM)
vortioxetine	Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK)
vortioxetine	TAKEDA PHARMACEUTICAL CO LTD (TKPHF)

Phase 2(17)

Drug	Company
ABV-1504	ABVC BIOPHARMA, INC. (ABVC)
ACP-211	ACADIA PHARMACEUTICALS INC (ACAD)
ALTO-203	Alto Neuroscience, Inc. (ANRO)
ELE-101	Atai Beckley N.V. (ATAI)
Icalcaprant	AbbVie Inc. (ABBV)
itruvone	Vistagen Therapeutics, Inc. (VTGN)
mij821	Novartis AG (NVS)
MM120	Definium Therapeutics Inc. (DFTX)
nbi-1070770	NEUROCRINE BIOSCIENCES INC (NBIX)
nmra-335140	Neumora Therapeutics, Inc. (NMRA)
ono-1110	NYMOX PHARMACEUTICAL CORP (NYMXF)
ONO-1110	Ultragenyx Pharmaceutical Inc. (RARE)
Pimavanserin	ACADIA PHARMACEUTICALS INC (ACAD)
Psilocybin	COMPASS Pathways plc (CMPS)
sls-002	SEELOS THERAPEUTICS, INC. (SEEL)
spn-821	SUPERNUS PHARMACEUTICALS, INC. (SUPN)
SPT-300	Crinetics Pharmaceuticals, Inc. (CRNX)

Phase 1(2)

Drug	Company
BHV-7000	Biohaven Ltd. (BHVN)
ketamir-2	MIRA PHARMACEUTICALS, INC. (MIRA)

Preclinical(1)

Drug	Company
kv7 development candidates	Xenon Pharmaceuticals Inc. (XENE)

Phase 2/Phase 3(1)

Drug	Company
opakalim	Biohaven Ltd. (BHVN)

Phase 4(3)

Drug	Company
Naltrexone	COLLEGIUM PHARMACEUTICAL, INC (COLL)
Pimavanserin 34 milligrams [Nuplazid]	ACADIA PHARMACEUTICALS INC (ACAD)
Pimavanserin Tartrate 34 Mg ORAL CAPSULE [NUPLAZID]	ACADIA PHARMACEUTICALS INC (ACAD)

BioSniper tracks 56 drugs in development for Major Depressive Disorder across 40 companies.

There are 38 clinical trials targeting Major Depressive Disorder tracked by BioSniper.

The estimated prevalence of Major Depressive Disorder is approximately 5000.0 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.